Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons
08.10.2026 03:45
During the October 1 episode of Mad Money, Jim Cramer discussed Amgen Inc. (NASDAQ:AMGN) while reviewing the Dow Jones Industrial Average’s third-quarter performance. He then shifted his attention to Johnson & Johnson (NYSE:JNJ), as he said: In the end, I think the best lessons from the third quarter came from the 30 stocks in the […]
How ICOTYDE’s Long-Term Psoriasis Data At Johnson & Johnson (JNJ) Has Changed Its Investment Story
07.10.2026 07:17
Johnson & Johnson recently reported new two-year Phase 3 ICONIC-TOTAL data showing its oral peptide ICOTYDE® (icotrokinra) maintained skin clearance and consistent safety in adults and adolescents with high-impact plaque psoriasis through Week 112. The results highlight ICOTYDE’s potential appeal as a once-daily, targeted oral alternative for difficult-to-treat psoriasis areas such as scalp, genital skin, hands, feet and nails. We’ll now examine how ICOTYDE’s long-term psoriasis data fits...
Jim Cramer Has Soured on Intuitive Surgical (ISRG). The Reason is Johnson & Johnson
07.10.2026 03:43
Intuitive Surgical, Inc. (NASDAQ:ISRG) was turned down by Jim Cramer on Mad Money on October 6, when a caller asked whether the robotic surgery company counted as a broken stock rather than a broken company. The shares traded at around $404 on October 6, 7.82% lower over twelve months. His objection was not the company. […]
Johnson & Johnson CEO Says AI Has to Be Embraced
06.10.2026 16:29
Johnson & Johnson Chairman & CEO Joaquin Duato says artificial intelligence is a force multiplier and has to be embraced. He's on this week's episode of The David Rubenstein Show: Peer to Peer Conversations. This interview was recorded on June 16 in Washington.
Johnson & Johnson's Innovative Medicines Momentum Offsets MedTech Headwinds, RBC Capital Markets Says
06.10.2026 15:21
Johnson & Johnson's (JNJ) Innovative Medicines segment acceleration is helping overcome persistent h
PFE vs. JNJ: Which Stock Is the Better Value Option?
06.10.2026 14:40
PFE vs. JNJ: Which Stock Is the Better Value Option?
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
06.10.2026 14:38
J&J's MedTech faces Abiomed and competitive pressures, but Vision, Orthopedics and Surgery could drive a stronger second half.
Johnson & Johnson (JNJ) Earnings Expected to Grow: Should You Buy?
06.10.2026 13:00
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If The MiniMed Split-Off Stalls, What Happens To Your Medtronic Stock?
06.10.2026 12:18
Medtronic (MDT) is offering its shareholders a swap: hand in Medtronic shares and receive shares of MiniMed, its diabetes business. The offer is worth about $4 billion, and a Barron's report on October 2 said it is losing its allure. If you own Medtronic, you may wonder what a stalled swap would leave you holding. First, where does the swap stand today.
Botaretigene Sparoparvovec Market Size and Sales Forecast for X-Linked Retinitis Pigmentosa in the 7MM - 2034 | Clinical Momentum and Orphan Incentives Drive Growth
06.10.2026 11:17
Clinical efficacy, manageable safety, high unmet need and expedited regulatory pathways support market potential, while pricing, reimbursement and competition shape ROI.Dublin, Oct. 06, 2026 (GLOBE NEWSWIRE) -- "Botaretigene Sparoparvovec Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The "Botaretigene sparoparvovec Sales Forecast and Market Size Analysis - 2034" report delivers a comprehensive assessment of the investigational gene therapy's
RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $290
06.10.2026 09:15
RBC Capital analyst Trung Huynh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and raises the price target from $287 to $290.
Johnson & Johnson: The Next Patent Cliff Will Test A Replacement Engine That It Is Already Working On
06.10.2026 06:14
Johnson & Johnson (JNJ) stock's 2Q26 sales rose 6.6% despite STELARA drag. Read here for a detailed investment analysis.
EADV26: Key late-stage readouts from the conference
05.10.2026 11:57
Clinical Trials Arena brings you the highlights from EADV 2026, covering key eczema and psoriasis readouts from notable biotech and pharma players.
Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?
02.10.2026 08:47
Intuitive Surgical (ISRG) grows faster and earns a higher operating margin than any of the five rivals in its health care peer group. It is also the most expensive of the six when price is measured against earnings. It holds that place even after its stock fell 10.3% over the past twelve months. How much more do you pay for a dollar of Intuitive's earnings than for a dollar of a rival's.
Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?
02.10.2026 08:47
Intuitive Surgical (ISRG) grows faster and earns a higher operating margin than any of the five rivals in its health care peer group. It is also the most expensive of the six when price is measured against earnings. It holds that place even after its stock fell 10.3% over the past twelve months. How much more do you pay for a dollar of Intuitive's earnings than for a dollar of a rival's.
BofA thinks Wall Street is underestimating one J&J drug
02.10.2026 01:03
Bank of America nearly doubled its peak sales estimate for one Johnson & Johnson drug ahead of the company’s third-quarter earnings.
JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning
01.10.2026 16:15
Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
01.10.2026 11:45
JACKSONVILLE, Fla., October 01, 2026--New global survey by Johnson & Johnson finds most women don’t connect eye health changes with menopause
5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)
01.10.2026 11:15
With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?
What is Johnson & Johnson’s (JNJ) Economic Moat, and is it Widening or Narrowing?
01.10.2026 00:12
Johnson & Johnson (NYSE:JNJ) closed at $264.74 on September 30, almost 43% higher than a year ago and within a few percent of its record. The company is worth about $638 billion and turns 29.19% of its $97.93 billion in revenue into operating profit. READ ALSO: Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid […]